Cetus/Roche
Executive Summary
Firms are not involved in a patent dispute over development of interleukin-2 as was stated in April 10 issue, T&G-2. Cetus and Roche, in fact, signed a cross-licensing agreement for the biotech product on Dec. 22 ("The Pink Sheet" Jan. 2, T&G-5).